Led · Series B · Mar 2017

EyeYon Medical develops EndoArt®, a synthetic artificial endothelial layer designed to be attached to the posterior corneal surface to treat chronic corneal edema caused by endothelial dysfunction. The minimally invasive implant aims to replace dysfunctional endothelium, restore corneal homeostasis and reduce vision loss, offering a potentially safer and simpler alternative to corneal transplantation. The company also markets an FDA‑approved therapeutic contact lens, Hyper CL™, for various corneal pathologies. EyeYon says additional funding will accelerate pivotal clinical studies and support regulatory clearances across multiple regions. The company has generated first‑in‑human clinical evidence validating EndoArt® safety and is now pursuing expanded trials. Recent financing is intended to advance EndoArt® clinical trials in the USA, China and Europe and to broaden surgeon access to the therapy. EyeYon Medical is an Israeli medtech company founded in 2011 at the VLX Technological Incubator by ophthalmologists. The company is developing a silicone disc implanted in place of the corneal endothelium as a synthetic substitute for corneal transplants. The new capital will be used to finance human clinical trials for that implant. EyeYon also markets Hyper-CL, a contact lens that has received FDA and CE certification and is being sold in Spain, Poland, India, and the US. The company has raised a total of $10 million to date. Nahum Ferera serves as CEO.